戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  positive for ZIKV infection, 27 had GBS (18 demyelinating, 8 axonal, and 1 Miller Fisher syndrome),
2 ctions in relation to lesion morphometry and demyelinating activity in MS patients.
3                    Following exposure to the demyelinating agent cuprizone, however, GALC +/- animals
4 robust remyelinating activity in response to demyelinating agents in both chronic cuprizone and acute
5 in both severity and age of onset, including demyelinating and axonal forms of Charcot-Marie Tooth (C
6 gnostic evidence of a length-dependent mixed demyelinating and axonal polyneuropathy.
7 the frequency and distribution of paediatric demyelinating and encephalitic syndromes with MOG antibo
8   Multiple sclerosis (MS) is an inflammatory demyelinating and neurodegenerative disease of the centr
9                                              Demyelinating and neurodegenerative diseases evoked cont
10 hey differ from multiple sclerosis and other demyelinating and non-demyelinating conditions in their
11 ultiple sclerosis is a chronic inflammatory, demyelinating, and neurodegenerative disease affecting t
12 B and the extent of reactive astrogliosis in demyelinating areas and in in vitro assays.
13  sclerosis, but also show that even a single demyelinating attack-when associated with white matter l
14               Of interest to the etiology of demyelinating autoimmune disease is the potential to abe
15              Multiple sclerosis is a chronic demyelinating autoimmune disease of the CNS with no know
16  the common forms of either acute or chronic demyelinating autoimmune neuropathy.
17                 Multiple sclerosis (MS) is a demyelinating, autoimmune disease of the central nervous
18 ocal leukoencephalopathy (PML), an oft-fatal demyelinating brain disease in individuals receiving imm
19 irus from patients with the frequently fatal demyelinating brain disease progressive multifocal leuko
20                         This data shows that demyelinating brain lesions are associated with the pres
21                                              Demyelinating central nervous system (CNS) disorders lik
22 morphological parameters in a mouse model of demyelinating CMT1B, without exacerbating the toxic gain
23 e the metabolic properties of T cells in the demyelinating CNS in vivo.
24 lls that mediate ongoing inflammation in the demyelinating CNS.
25 nctional deficits underlying diseases with a demyelinating component.
26 le sclerosis and other demyelinating and non-demyelinating conditions in their prognosis and treatmen
27 an syndrome or Vogt-Koyanagi-Harada disease; demyelinating conditions such as multiple sclerosis or n
28  has been shown to enhance myelination under demyelinating conditions, successfully reversed social a
29 ic relevance in multiple sclerosis and other demyelinating conditions.
30 MOG antibody disease both considered primary demyelinating conditions.
31 tance when understanding myelin assembly and demyelinating conditions.
32 s in the meninges and pronounced in actively demyelinating cortical lesions, retrograde degeneration
33 ler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD), a well-established ani
34 hrough the alternative complement cascade in demyelinating disease and identify a strategy to prevent
35 ation abnormalities seen in association with demyelinating disease and optic neuritis, although evide
36 motes recovery from preexisting inflammatory demyelinating disease and suggest that this protection i
37 irmed that NFM was not a critical Ag driving demyelinating disease because NFM18-30-specific T cells
38 unogenic in C57BL/6 mice but fails to induce demyelinating disease by polyclonal T cells despite havi
39 al leukoencephalopathy (PML) is a lethal CNS demyelinating disease caused by the human neurotropic po
40 that has been linked to JME, an inflammatory demyelinating disease in Japanese macaques that mimics m
41  patient who died from a rapidly progressing demyelinating disease known as progressive multifocal le
42                                          The demyelinating disease multiple sclerosis (MS) has an ear
43 PCs), thereby impeding remyelination, in the demyelinating disease multiple sclerosis (MS).
44 functional impairment that characterizes the demyelinating disease multiple sclerosis (MS).
45  myelin repair in animal models of the human demyelinating disease multiple sclerosis (MS).
46 lination in a preclinical model of the human demyelinating disease multiple sclerosis (MS).IMPORTANCE
47 lation and is the causative agent of a fatal demyelinating disease of the central nervous system (CNS
48                  NMOSD is a recently defined demyelinating disease of the central nervous system (CNS
49   Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS
50      MS is a chronic idiopathic inflammatory demyelinating disease of the central nervous system (CNS
51 gressive multifocal leukoencephalopathy is a demyelinating disease of the central nervous system caus
52  Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system that
53         Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system trad
54 h multiple sclerosis, a chronic inflammatory demyelinating disease of the central nervous system with
55  leukoencephalopathy (PML) is an often-fatal demyelinating disease of the central nervous system.
56  sclerosis (MS) (n=43,879), an inflammatory, demyelinating disease of the central nervous system.
57 sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system.
58 iple sclerosis (MS) is the most common human demyelinating disease of the central nervous system.
59 ple sclerosis (MS) is known as an autoimmune demyelinating disease of the central nervous system.
60               Centres managing patients with demyelinating disease of the CNS across Australia and Ne
61 nd multiple sclerosis (MS), an inflammatory, demyelinating disease of the CNS of unknown etiology.
62 sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the CNS that causes disability
63 ncephalomyelitis is a CD4(+) T cell-mediated demyelinating disease of the CNS that serves as a model
64 e sclerosis (MS), a chronic inflammatory and demyelinating disease of the CNS.
65 T Multiple sclerosis (MS) is an inflammatory demyelinating disease of the CNS.
66 tiple sclerosis (MS) is a neuroinflammatory, demyelinating disease of the CNS.
67         Multiple sclerosis (MS) is a chronic demyelinating disease of the CNS.
68  of multiple sclerosis (MS), an inflammatory demyelinating disease of the CNS.
69             Multiple sclerosis is a chronic, demyelinating disease of the CNS.
70  Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the CNS.
71 ultiple Sclerosis (MS) is an immune-mediated demyelinating disease of the human central nervous syste
72 therapeutic modulation of ERK1/2 activity in demyelinating disease or peripheral neuropathies must be
73             We propose that the inflammatory demyelinating disease process in early multiple sclerosi
74 -specific virus, causes the aggressive brain-demyelinating disease progressive multifocal leukoenceph
75 e multicentre prospective Canadian Pediatric Demyelinating Disease Study (CPDDS).
76  disorders including traumatic brain injury, demyelinating disease, Alzheimer's disease (AD), and Par
77  hemorrhage, intracranial hemorrhage, spine, demyelinating disease, and epileptic patients.
78                             In the 2.3% with demyelinating disease, gabapentin was the most likely se
79 yelination similar in pathology to the human demyelinating disease, multiple sclerosis.
80 ression, JCV can infect the brain, causing a demyelinating disease, progressive multifocal leukoencep
81 tral nervous system and chronic inflammatory demyelinating disease, providing an experimental animal
82 composition and low MBP concentration, as in demyelinating disease, show structural instabilities and
83       In glaucoma, which is not considered a demyelinating disease, the observed increase in radial d
84 rimate model of MS, and two rodent models of demyelinating disease, we investigated synapse changes i
85 ven by excessive microglial pruning early in demyelinating disease, which can be rescued by inhibitin
86 ultifocal leukoencephalopathy (PML), a fatal demyelinating disease.
87 al leukoencephalopathy (PML), a rare, fatal, demyelinating disease.
88 ler's murine encephalomyelitis virus-induced demyelinating disease.
89 ler's murine encephalomyelitis virus-induced demyelinating disease.
90 lammatory and proliferative genes to promote demyelinating disease.
91 ENT Multiple sclerosis is a severe, chronic, demyelinating disease.
92 ation in OPCs, contributing to Th17-mediated demyelinating disease.
93 rsistence associated with an immune-mediated demyelinating disease.
94 nent role in the development of TMEV-induced demyelinating disease.
95 t leukodystrophy (ADLD), a fatal adult onset demyelinating disease.
96  potential therapeutic target for autoimmune demyelinating disease.
97 nic and regulatory roles these cells play in demyelinating disease.
98 lerosis (MS) is a heterogeneous inflammatory demyelinating disease.
99 te ratio, 0.90 [95% CI, 0.70-1.15]) or other demyelinating diseases (crude incidence rates, 7.54 even
100  spectrum disorders (NMOSD) are inflammatory demyelinating diseases (IDD) with a specific biomarker,
101 neficial both for enhancing remyelination in demyelinating diseases and for increasing neural plastic
102  the potential for enhanced remyelination in demyelinating diseases and increased neural plasticity i
103 ors may prove safe and effective in treating demyelinating diseases and potentially other autoimmune
104 ted in the pathogenesis of neuroinflammatory demyelinating diseases as well as enhancement of the mig
105                            Treatment against demyelinating diseases has been elusive, partially becau
106 yelin can be replaced after injury or during demyelinating diseases in a regenerative process called
107 is result in the impairment of recovery from demyelinating diseases in the adult.
108 al prerequisite for developing therapies for demyelinating diseases in the PNS.
109 s for the application of LRRK2 inhibitors in demyelinating diseases in which oligodendrocyte cell-dea
110                                           In demyelinating diseases including multiple sclerosis (MS)
111                               Progression of demyelinating diseases is caused by an imbalance of two
112 t that oral GlcNAc may be neuroprotective in demyelinating diseases like MS.
113 portant role in cognitive development and in demyelinating diseases like multiple sclerosis (MS), whe
114 reported in patients that recover from acute demyelinating diseases such as Guillain-Barre syndrome.
115 tions including central nervous system (CNS) demyelinating diseases such as multiple sclerosis (MS) a
116  therapeutic approaches for the treatment of demyelinating diseases such as multiple sclerosis (MS).S
117 nstitute clinically debilitating sequelae in demyelinating diseases such as multiple sclerosis, but t
118  axons, associated with traumatic injury and demyelinating diseases such as multiple sclerosis, cause
119                                           In demyelinating diseases such as multiple sclerosis, disru
120 loping new therapeutic tools to intervene in demyelinating diseases such as multiple sclerosis.
121 o ameliorate the devastating consequences of demyelinating diseases such as multiple sclerosis.
122 lination underlies the progressive nature of demyelinating diseases such as multiple sclerosis.
123 on's, and amyotrophic lateral sclerosis, and demyelinating diseases such as multiple sclerosis.
124 hat Shp2 is a relevant therapeutic target in demyelinating diseases such as multiple sclerosis.SIGNIF
125 otton rat Sigmodon hispidus For a long time, demyelinating diseases were considered to be autoimmune
126 iple sclerosis cases and 3300 cases of other demyelinating diseases were identified, of which 73 and
127 peutic enhancement of remyelination in those demyelinating diseases where GPR17 is highly expressed,
128 hich the olfactory system is affected in CNS demyelinating diseases, and raises intriguing questions
129 hat is frequently used to study inflammatory demyelinating diseases, due to increased resistance of t
130                     Myelin loss occurring in demyelinating diseases, including multiple sclerosis, is
131  finding may have important implications for demyelinating diseases, psychiatric disorders, and cogni
132 BP is an abundant myelin protein involved in demyelinating diseases, such as multiple sclerosis.
133                                  Because, in demyelinating diseases, the myelin formed during remyeli
134  development in multiple sclerosis and other demyelinating diseases.
135 his pool of progenitors to replace myelin in demyelinating diseases.
136 mportant role in the pathogenesis underlying demyelinating diseases.
137 xonal degeneration that occurs in peripheral demyelinating diseases.
138 ying pathogenesis in autoimmune inflammatory demyelinating diseases.
139 e development of multiple sclerosis or other demyelinating diseases.
140 nd development of regenerative therapies for demyelinating diseases.
141  for therapeutic targeting of LSDs and other demyelinating diseases.
142 t enhance remyelination in patients with CNS demyelinating diseases.
143 e significant potential for treating chronic demyelinating diseases.
144 for enhancing remyelination in patients with demyelinating diseases.
145 MAD (pSMAD) 1/5/8 in lesions of MS and other demyelinating diseases.
146  inflammation and promote myelin recovery in demyelinating diseases.SIGNIFICANCE STATEMENT Reducing v
147 ising strategies to advance the treatment of demyelinating diseases.SIGNIFICANCE STATEMENT The benefi
148 kodystrophy (GLD, Krabbe disease) is a fatal demyelinating disorder caused by a deficiency in the lys
149   Multiple Sclerosis (MS) is an inflammatory demyelinating disorder in which remyelination failure co
150 ic oligodendrocyte loss, which occurs in the demyelinating disorder multiple sclerosis (MS), contribu
151         Multiple sclerosis (MS) is a chronic demyelinating disorder of the central nervous system (CN
152         Multiple sclerosis (MS) is a chronic demyelinating disorder of the CNS characterized by immun
153          Multiple sclerosis is an autoimmune demyelinating disorder of the CNS, characterized by infl
154   Multiple sclerosis is a chronic autoimmune demyelinating disorder of the CNS.
155   Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the CNS.
156 d disease (MOG-AAD) is a recently recognized demyelinating disorder predominantly affecting children
157  effective remyelination in the treatment of demyelinating disorders and in identifying pathways invo
158  of MOG-Abs and their role in autoimmune and demyelinating disorders of the CNS.
159 ay be a therapeutically tractable target for demyelinating disorders of the CNS.SIGNIFICANCE STATEMEN
160 disseminated encephalomyelitis) and from non-demyelinating disorders such as chronic small vessel dis
161 nation.SIGNIFICANCE STATEMENT Myelin loss in demyelinating disorders such as multiple sclerosis resul
162 evelopment of therapies to promote repair in demyelinating disorders such as multiple sclerosis.
163 ompensate myelin loss in the early phases of demyelinating disorders, this spontaneous reparative pot
164 nisms sustaining endogenous remyelination in demyelinating disorders, we focused our attention on end
165 vaccination against HSV-1 can help to combat demyelinating disorders.
166 enues for treatment of neurodegenerative and demyelinating disorders.
167 ons, but also provide potential insight into demyelinating disorders.
168 tion contributes to remyelination failure in demyelinating disorders.
169 rapeutic potential to boost remyelination in demyelinating disorders.
170 s may be beneficial in neuroinflammatory and demyelinating disorders.
171 ew strategies for promoting myelin repair in demyelinating disorders.
172 ged myelin deteriorates during the course of demyelinating disorders.
173 ation between HSV-1 infection and multifocal demyelinating disorders.
174 accination against HSV-1 may protect against demyelinating disorders.IMPORTANCE Our work demonstrates
175            The resultant phenotype is severe demyelinating DSN with onset at two years of age, confir
176 nflammatory neuropathy with mixed axonal and demyelinating electrophysiology.
177  recently isolated from JM with inflammatory demyelinating encephalomyelitis (JME).
178             At follow up, 55% had a clinical demyelinating episode involving the brain; 30% of cases
179 ole of cholesterol in promoting repair after demyelinating episodes.
180  reduces the risk of conversion from a first demyelinating event (also known as a clinically isolated
181   Early treatment following a first clinical demyelinating event (FCDE) delays further disease activi
182  Study with 127 cases having a classic first demyelinating event followed for 5 years from onset.
183 und to attenuate the conversion from a first demyelinating event to clinically definite MS in a phase
184 rsion in individuals experiencing an initial demyelinating event.
185 y, we evaluated the role of CRYAB in primary demyelinating events.
186 on of NCS can be difficult and none of these demyelinating findings are specific for CIDP.
187  to 40% of boys develop a severe progressive demyelinating form of ALD, cerebral ALD, resulting in re
188 gical tests were consistent with the primary demyelinating form of the disease.
189 opathy with liability to pressure palsies or demyelinating forms of Charcot-Marie-Tooth disease.
190 isease type 4C and potentially other similar demyelinating inherited neuropathies.
191 icroglial subtypes were also found following demyelinating injury in mice, at least one of which was
192 yelinating drug for the treatment of chronic demyelinating injury in multiple sclerosis.
193  into Gamt-deficient and wild-type mice with demyelinating injury reduced oligodendrocyte apoptosis,
194                   Using lysolecithin-induced demyelinating injury to the mouse spinal cord, we charac
195  timed motor learning improves recovery from demyelinating injury via enhanced remyelination from new
196 human white matter injury from normal rodent demyelinating injury.
197 rs myelin production and remyelination after demyelinating injury.
198  hormone (T3)-free window, with or without a demyelinating insult, provides a favorable environment f
199 earance and diminished remyelination after a demyelinating insult.
200 roptotic, and apoptotic cell death caused by demyelinating, ischemic, and traumatic injuries, implyin
201 iple sclerosis pathology outside the classic demyelinating lesion.
202                  All presented with cerebral demyelinating lesions and gadolinium enhancement.
203                                     Cortical demyelinating lesions are clinically important in multip
204 r Th cells that can drive the development of demyelinating lesions are phenotypically diverse or aris
205     Here, we developed a method to label CNS demyelinating lesions by the intraperitoneal injection o
206 S autoimmunity characterized by inflammatory demyelinating lesions confined to optic nerves and spina
207  sulfate proteoglycans (CSPGs) accumulate at demyelinating lesions creating a nonpermissive environme
208                       We now report actively demyelinating lesions in patients with multiple sclerosi
209                                              Demyelinating lesions were induced in the rat spinal dor
210                                              Demyelinating lesions were not centered on the injection
211  early axonal pathology outside inflammatory demyelinating lesions.
212 ntributors to thalamic atrophy than thalamic demyelinating lesions.
213 associated inflammation and the formation of demyelinating lesions.
214  pipelines we were able to: (1) Discriminate demyelinating macrophages from the resident microglial p
215 ct proline dyad in the FP of the recombinant demyelinating MHV strain plays a crucial role in translo
216 ting a single proline residue in the FP of a demyelinating MHV strain, we found that two central, con
217 spectrum is broad and encompasses axonal and demyelinating motor and sensory neuropathies, including
218 form in vivo fate-tracing in an inflammatory demyelinating mouse model.
219     The presence of myelinosomes in actively demyelinating MS lesions suggests that oligodendrocyte d
220 ially phosphorylated in astrocytes in active demyelinating MS lesions, as well as in cuprizone-induce
221 %) loss of anterior horn neurons, notably in demyelinating MS lesions.
222 at peripheral nerve and their dynamics after demyelinating nerve injury.
223 , implicating c-Jun as a potential player in demyelinating neuropathies.
224 ses myelin genes, and has been implicated in demyelinating neuropathies.
225 e axonal degeneration observed in peripheral demyelinating neuropathies.
226 es proof of principle for treating inherited demyelinating neuropathies.
227  neuropathy, and some paraprotein-associated demyelinating neuropathies.
228 ed as HRs [95% CIs]) of chronic inflammatory demyelinating neuropathy (2.8; 1.6-5.1; P = .001), auton
229 n of OGT (OGT-SCKO mice) causes a tomaculous demyelinating neuropathy accompanied with progressive ax
230 ifically whether MMN represents an axonal or demyelinating neuropathy and whether the underlying path
231         The OGT-SCKO mice develop tomaculous demyelinating neuropathy characterized by focal thickeni
232 B (CMT1B) neuropathy in humans and a similar demyelinating neuropathy in transgenic mice, is instead
233 opsy showed a mixed predominantly axonal and demyelinating neuropathy in two sCJDMV2K.
234 tory VEGF testing for patients with acquired demyelinating neuropathy is a cost-effective strategy al
235 common form of hereditary autosomal dominant demyelinating neuropathy known as Charcot-Marie-Tooth di
236  4C is the most common recessively inherited demyelinating neuropathy that results from loss of funct
237 ts with recurrent acute predominantly motor, demyelinating neuropathy with conduction block, and chro
238 for patients with acute predominantly motor, demyelinating neuropathy with conduction block, and seco
239               Testing patients with acquired demyelinating neuropathy with serum vascular endothelial
240 tory VEGF testing for patients with acquired demyelinating neuropathy would lead to annual cost-savin
241 ch difficulties) and peripheral (early onset demyelinating neuropathy) neurological involvement, who
242 1X), one of the commonest forms of inherited demyelinating neuropathy, results from GJB1 gene mutatio
243 GF testing for all patients with an acquired demyelinating neuropathy.
244 linical and electrophysiological evidence of demyelinating neuropathy.
245 experimental optic neuritis, an inflammatory demyelinating optic nerve condition that occurs in MS an
246                                              Demyelinating optic nerve inflammation, termed optic neu
247 R hypersignal was not related to ischemic or demyelinating optic nerve pathology but was associated w
248                                        Acute demyelinating optic neuritis, a common feature of multip
249 th relapsing multiple sclerosis with chronic demyelinating optic neuropathy on stable immunomodulator
250          Electrophysiologic studies showed a demyelinating or axonal pattern in, respectively, 60% an
251 on with implications in axonal repair in CNS demyelinating pathologies.SIGNIFICANCE STATEMENT The dep
252 ther central nervous system disorders with a demyelinating pathology.media-1vid110.1093/brain/aww039_
253                                    Inherited demyelinating peripheral neuropathies are progressive in
254 a potential opportunity for the treatment of demyelinating peripheral neuropathies.
255 ie-Tooth disease type 4B1 (CMT4B1), a severe demyelinating peripheral neuropathy characterized by mye
256 sociated with Charcot-Marie-Tooth 1B (CMT1B) demyelinating peripheral neuropathy in human and mouse.
257  aged Prnp(ZH3/ZH3) mice developed a chronic demyelinating peripheral neuropathy, confirming the cruc
258 lly authentic model of CMT1X that develops a demyelinating peripheral neuropathy.
259  providing robust evidence that the profound demyelinating phenotype observed in the dorsal columns o
260  of a group of MOG-Ab-positive patients with demyelinating phenotypes.
261 ssociation between CD and acute inflammatory demyelinating polyneuropathy (0.8; 0.3-2.1; P = .68).
262 nd less frequently in the acute inflammatory demyelinating polyneuropathy (AIDP) type of GBS or in ce
263 The association between chronic inflammatory demyelinating polyneuropathy (CIDP) and diabetes is unce
264 ar clinical features of chronic inflammatory demyelinating polyneuropathy (CIDP) except 'motor neurop
265                         Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediate
266 thirds of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) need long-term intra
267 of nerve hypertrophy in chronic inflammatory demyelinating polyneuropathy (CIDP), magnetic resonance
268  in the pathogenesis of chronic inflammatory demyelinating polyneuropathy (CIDP).
269 n reported as mimicking chronic inflammatory demyelinating polyneuropathy (CIDP).
270  were consistent with the acute inflammatory demyelinating polyneuropathy subtype of the Guillain-Bar
271 ropathy and variants of chronic inflammatory demyelinating polyneuropathy, account for a proportion o
272 uillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropath
273 uillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropath
274 past medical history of chronic inflammatory demyelinating polyneuropathy, Sjogren's syndrome, and sy
275 rse myelitis, and 1 had chronic inflammatory demyelinating polyneuropathy.
276 %) with newly diagnosed chronic inflammatory demyelinating polyneuropathy.
277  Peripheral neuropathies included axonal and demyelinating polyradiculoneuropathies (n = 2), length-d
278                         Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) consists of
279                         Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare an
280                         Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an inflam
281 orrectly diagnosed with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
282 e fibre types including chronic inflammatory demyelinating polyradiculoneuropathy (CIDP: N=20); amylo
283 ssel-wall fibrosis was detected early in the demyelinating process, even in lesions <2 weeks old, tho
284                Because the pathogenicity and demyelinating properties of anti-MAG autoantibodies are
285 utoreactive T-cell and microglial/macrophage demyelinating response is critical to effectively target
286 pical' subtypes, such as multifocal acquired demyelinating sensory and motor neuropathy (Lewis-Sumner
287          Applying lysolecithin-induced focal demyelinating spinal cord lesions, we found that FA synt
288 tive immune responses as well as the chronic demyelinating stage of disease in response to JHMV infec
289 (Lewis-Sumner syndrome) and 'distal acquired demyelinating symmetric neuropathy', possibly having dif
290 ssigned participants who had had their first demyelinating symptoms within the previous 180 days to r
291     Most children who experience an acquired demyelinating syndrome of the central nervous system wil
292 1, 2013, and Dec 31, 2018, 239 children with demyelinating syndromes (cohort A) and 296 with encephal
293 QP4-IgG-negative optic neuritis (n=4), other demyelinating syndromes (n=3) and multiple sclerosis (n=
294  wider than previously reported and includes demyelinating syndromes and encephalitis.
295 ospective observational study, children with demyelinating syndromes and with encephalitis other than
296                        Atypical inflammatory demyelinating syndromes are rare disorders that differ f
297                Fifty-three participants with demyelinating syndromes eventually received a diagnosis
298 of 132 paediatric participants with acquired demyelinating syndromes followed for a median of 4.4 yea
299 tence of sexual dimorphism in the effects of demyelinating syndromes on normal-appearing white matter
300 tein (MOG) antibodies are usually focused on demyelinating syndromes, but the entire spectrum of MOG

 
Page Top